-
Results from recent published trials have shown much promise in the use of trastuzumab (Herceptin) plus adjuvant chemotherapy in patients with HER2-positive early-stage breast cancer.
-
The FDA has begun requiring drug manufacturers to submit prescription drug label information to the agency in a new electronic format.
-
Mechanism of action, Pharmacokinetics, Dosage, Clinical studies, Strengths, Weaknesses, Drug interactions, Adverse reactions, Warnings/precautions, Monitoring, Cost comparison, Summary and recommendations
-
Nelarabine (Arranon) by GlaxoSmithKline. The FDA has approved nelarabine (Arranon) to treat adults and children with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), whose disease has not responded to or has relapsed following at least two chemotherapy regimens.
-
Much has been written about drugs and their adverse effects (AEs). But two pharmacists saw the need for a central source of information for an important subset of adverse effects: drug-induced diseases.
-
Seniors finally had the opportunity to enroll in a Medicare Part D plan beginning Nov. 15. More than half of those eligible, however, still are confused about the governments new prescription drug plan benefit, according to a Kaiser Health Poll Report conducted in August.
-
Researchers examining adverse drug events (ADEs) at a Veterans Affairs (VA) Hospital in Salt Lake City found surprising results. The computerized physician order entry (CPOE) system had reduced ADEs in some areas, but the rates were higher than expected in decision support.
-
The Joint Commission on Accreditation of Healthcare Organizations in Oakbrook Terrace, IL, has announced its 2006 National Patient Safety Goals and related requirements. Several of the revisions to last years goals involve medication safety.
-
Lenalidomide (Revlimid) can help some patients with myelodysplastic syndromes (MDS) avoid the need for blood transfusions, and even reduce or eliminate the genetic abnormality that characterizes the disease in this subset of patients, according to a new study.
-
The Centers for Disease Control (CDC) in Atlanta has announced that the supply of inactivated influenza vaccine projected for the 2005-06 season should be adequate to meet the historical demand from persons in the priority groups established by Advisory Committee on Immunization Practices (ACIP) during the 2004-05 season.
